MRS Scan for Spinal Cord Lesions
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if Magnetic Resonance Spectroscopy (MRS), a special type of MRI, can effectively examine spinal cord lesions. It includes two groups: healthy volunteers and patients with leptomeningeal disease (LMD), a condition affecting the central nervous system. Healthy volunteers should not have spinal issues such as back pain or previous surgeries, while patients should have LMD but no spinal cord lesions. The goal is to assess whether MRS can serve as a useful tool for evaluating spinal health. As an unphased trial, this study allows participants to contribute to groundbreaking research that could enhance diagnostic techniques for spinal health.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this MRS scan is safe for assessing spinal cord lesions?
Research has shown that Magnetic Resonance Spectroscopy (MRS) scans are generally safe. Studies have found that MRS scans provide more detailed information about the spinal cord than regular scans. They function like a more advanced MRI, helping doctors better understand the spine's internal conditions.
MRS is non-invasive, meaning it doesn't involve surgery or entering the body. No specific reports of serious side effects from MRS use exist, suggesting most people tolerate the procedure well. MRI-based techniques like MRS have been used safely for many years because they do not use radiation.
For those considering joining a trial involving MRS, these findings suggest that the procedure is safe and generally well-tolerated.12345Why are researchers excited about this trial?
Researchers are excited about the Magnetic Resonance Spectroscopy (MRS) scan for spinal cord lesions because it offers a unique way to analyze the biochemical changes in the spinal cord non-invasively. Unlike traditional MRI scans that provide structural images, MRS can detect metabolic changes, potentially allowing for earlier and more precise diagnosis of spinal cord abnormalities. This technique could lead to better understanding and monitoring of spinal cord conditions, which may improve treatment outcomes in the long run.
What evidence suggests that MRS is effective for assessing spinal cord lesions?
Studies have shown that Magnetic Resonance Spectroscopy (MRS) effectively assesses changes in spinal cord lesions. MRS provides detailed information about tissue chemistry, aiding in understanding the condition of these lesions. Research indicates that MRS is non-invasive and can detect chemical changes that regular MRI scans might miss. Although results can vary, MRS has been linked to better outcomes in some cases of spinal cord injury. Overall, MRS is considered a promising tool for evaluating spinal cord health. Participants in this trial will undergo MRS scans to further explore its effectiveness in assessing spinal cord lesions.13467
Who Is on the Research Team?
Rami Eldaya, MD
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 without spinal cord lesions, prior spinal surgery, implantable devices, MR claustrophobia, or degenerative back conditions. It includes those at high risk for LMD needing CNS radiation and healthy volunteers with no history of cancer or demyelinating diseases.Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Implementation of Magnetic Resonance Spectroscopy (MRS) on the spinal cord to assess lesions
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Magnetic Resonance Spectroscopy (MRS) Scan
Magnetic Resonance Spectroscopy (MRS) Scan is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Diagnostic imaging of spinal cord lesions
- Characterization of spinal cord tumors
- Differentiation of benign from malignant lesions
- Diagnostic imaging of spinal cord lesions
- Characterization of spinal cord tumors
- Differentiation of benign from malignant lesions
- Diagnostic imaging of spinal cord lesions
- Characterization of spinal cord tumors
- Differentiation of benign from malignant lesions
- Diagnostic imaging of spinal cord lesions
- Characterization of spinal cord tumors
- Differentiation of benign from malignant lesions
- Diagnostic imaging of spinal cord lesions
- Characterization of spinal cord tumors
- Differentiation of benign from malignant lesions
- Diagnostic imaging of spinal cord lesions
- Characterization of spinal cord tumors
- Differentiation of benign from malignant lesions
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor